Zobrazeno 1 - 7
of 7
pro vyhledávání: '"N C, Saccoia"'
Publikováno v:
Journal of Liquid Chromatography & Related Technologies. 19:2385-2394
Diltiazem (DTZ) is an anti-hypertensive and anti-anginal agent which is also used clinically as a metabolic inhibitor to reduce cyclosporin-A metabolism. The present communication describes an HPLC/UV method for measuring DTZ and 3 of its major metab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49fef8c85089d3d37f540296eb4a99e7
https://doi.org/10.1080/10826079608014024
https://doi.org/10.1080/10826079608014024
Publikováno v:
Journal of Liquid Chromatography. 17:4185-4193
Dextromoramide is a narcotic analgesic drug which has been said to be clinically useful where rapid onset and short duration of action is required. The present communication describes a modification of previous high performance liquid chromatographic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0db17297deee2b2816fb548f82e644df
https://doi.org/10.1080/10826079408013610
https://doi.org/10.1080/10826079408013610
Publikováno v:
European Journal of Clinical Pharmacology. 39:359-363
We have examined the current state of interference by digoxin-like immunoreactive substance(s) (DLIS) in 10 commercially available digoxin assay methods, ie 5 radioimmunoassays (RIA) and 5 non-radioactive immunoassays. Fifty-five specimens of materna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b9d51968390d84d92fd64a856b2affd
https://doi.org/10.1007/bf00315410
https://doi.org/10.1007/bf00315410
Publikováno v:
Palliative medicine. 10(4)
The extent of absorption and other pharmacokinetic parameters of dextromoramide following sublingual administration were assessed in five patients receiving chronic opioid analgesia. The use of the standard 5 mg tablet formulation was associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f630dffce6ed2db72cff4499e95fabf1
https://pubmed.ncbi.nlm.nih.gov/8931067
https://pubmed.ncbi.nlm.nih.gov/8931067
Publikováno v:
European Journal of Clinical Pharmacology. 40:199-200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a39ab2265ef0103e395f8ab1cad14e7
https://doi.org/10.1007/bf00280079
https://doi.org/10.1007/bf00280079
Publikováno v:
Therapeutic Drug Monitoring. 17:400
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbdf4769cc42bf8e6cd95023586623a8
https://doi.org/10.1097/00007691-199508000-00081
https://doi.org/10.1097/00007691-199508000-00081
Publikováno v:
Therapeutic drug monitoring. 11(4)
Fifteen cancer patients were studied following repeated courses of doxorubicin (12-44 mg/m2) (together with other anticancer agents) to consider the possibility of enhanced metabolism as a cause of the previously reported reduction in doxorubicin pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::829361b0340906e565638ce353494b78
https://pubmed.ncbi.nlm.nih.gov/2741185
https://pubmed.ncbi.nlm.nih.gov/2741185